cyclophosphamide + doxorubicin + filgrastim + paclitaxel

This is a combination chemotherapy regimen used primarily in the treatment of breast cancer. It consists of sequential administration of doxorubicin and cyclophosphamide followed by paclitaxel, with filgrastim (G-CSF) support to manage neutropenia and enable dose-dense scheduling. The regimen typically follows a dose-dense schedule where treatments are given every 2 weeks instead of the conventional 3-week intervals, which has been shown to improve disease-free and overall survival in node-positive breast cancer patients. The dose-dense approach is based on the theory that more frequent delivery of chemotherapy increases effectiveness by reducing the opportunity for cancer cells to recover between treatments.

Other names

dose-dense AC-Tdose-dense doxorubicin-cyclophosphamide followed by paclitaxel with filgrastim support